Research Continues for Stem Cell Treatment of ALS

The government may be in the midst of a shutdown, but thankfully clinical trials at universities continue to move forward, including the Neuralstem Phase II trial that is currently in progress at the University of Michigan in Ann Arbor, Michigan and at Emory University in Atlanta, Georgia. After positive Phase I trial results, Neuralstem was granted permission to move to a Phase II dose escalation and safety trial, which includes 15 patients who can be treated with up “to 40 injections and up to 400,000 cells per injection.” Dr. Eva Feldman, principal investigator for the Phase II trial at the University of Michigan, recently presented the results of the Phase I trial and gave an update about the Phase II trial, in which a third patient had just been treated. The therapy has been shown to be effective in rat models of ALS, and seemed to show promise as a potential ALS treatment in four of the fifteen patients treated in the Phase I.

Click here to read more about the study.

Share this: